Stoke Therapeutics (NASDAQ:STOK) Research Coverage Started at Wolfe Research

Wolfe Research started coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note issued to investors on Monday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $40.00 price objective on the stock.

A number of other brokerages have also weighed in on STOK. UBS Group set a $50.00 target price on Stoke Therapeutics in a research note on Monday, December 15th. HC Wainwright upped their price objective on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Loop Capital set a $35.00 target price on shares of Stoke Therapeutics in a research note on Monday, January 5th. JPMorgan Chase & Co. lifted their target price on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Monday, November 3rd. Finally, Chardan Capital increased their price target on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $39.25.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $35.50 on Monday. The stock has a market cap of $2.03 billion, a P/E ratio of 52.99 and a beta of 1.10. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $38.69. The firm’s fifty day moving average price is $31.76 and its 200-day moving average price is $28.10.

Insider Activity at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 13,430 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $32.27, for a total transaction of $433,386.10. Following the transaction, the director directly owned 49,124 shares of the company’s stock, valued at approximately $1,585,231.48. This trade represents a 21.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 8,785 shares of Stoke Therapeutics stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $31.29, for a total value of $274,882.65. Following the completion of the transaction, the general counsel owned 15,809 shares in the company, valued at approximately $494,663.61. This represents a 35.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 58,302 shares of company stock valued at $1,826,430. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its stake in shares of Stoke Therapeutics by 1.2% during the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock valued at $935,000 after purchasing an additional 354 shares during the period. Strs Ohio increased its stake in shares of Stoke Therapeutics by 9.4% in the fourth quarter. Strs Ohio now owns 7,000 shares of the company’s stock worth $222,000 after buying an additional 600 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after buying an additional 658 shares during the last quarter. Generali Investments Management Co LLC boosted its position in Stoke Therapeutics by 41.0% during the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock valued at $78,000 after buying an additional 718 shares during the period. Finally, Kestra Advisory Services LLC purchased a new stake in Stoke Therapeutics during the 4th quarter valued at $26,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.